Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127118991 | 12711899 | 1 | I | 201601 | 20160830 | 20160902 | 20160902 | EXP | CH-SM-2016-06935 | CH-BAYER-2016-168749 | BAYER | 70.00 | YR | E | F | Y | 58.00000 | KG | 20160902 | OT | CH | CH |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127118991 | 12711899 | 1 | PS | ULTRAVIST | IOPROMIDE | 1 | Intravenous bolus | 110 ML, UNK | 20220 | 110 | ML | SOLUTION FOR INJECTION | |||||||
| 127118991 | 12711899 | 2 | SS | ALIMTA | PEMETREXED DISODIUM | 1 | Intravenous drip | 900 MG, INFUSION DURATION 10 MINXCYCLE DURATION 21 DAYSX4 TOTAL | 0 | 900 | MG | ||||||||
| 127118991 | 12711899 | 3 | SS | ALIMTA | PEMETREXED DISODIUM | 1 | Intravenous drip | DOSE UNKNOWNXTOTAL 3 DOSES | 0 | ||||||||||
| 127118991 | 12711899 | 4 | SS | CISPLATIN EBEWE | CISPLATIN | 1 | Intravenous drip | 130 MG, INFUSION DURATION 60 MINXCYCLE DURATION 21DXTOTAL 4 DOSES | 0 | 130 | MG | ||||||||
| 127118991 | 12711899 | 5 | SS | APROVEL | IRBESARTAN | 1 | Oral | 150 MG NOT COMBINED WITH COAPROVEL | N | 0 | 150 | MG | |||||||
| 127118991 | 12711899 | 6 | SS | COAPROVEL | HYDROCHLOROTHIAZIDEIRBESARTAN | 1 | Oral | 1 DF, QD 150/12.5 MGXNOT COMBINED WITH APROVEL | N | 0 | 1 | DF | QD | ||||||
| 127118991 | 12711899 | 7 | SS | PANTOZOL | PANTOPRAZOLE SODIUM | 1 | Oral | 40 MG, BID (INITIAL DOSE 40 MG/D) | 0 | 40 | MG | BID | |||||||
| 127118991 | 12711899 | 8 | SS | XENETIX | IOBITRIDOL | 1 | Intravenous bolus | 110 ML | 0 | 110 | ML | ||||||||
| 127118991 | 12711899 | 9 | C | ATENOLOL. | ATENOLOL | 1 | Oral | 50 MG, QD | 0 | 50 | MG | QD | |||||||
| 127118991 | 12711899 | 10 | C | EZETROL | EZETIMIBE | 1 | Oral | 100 MG, QD | 0 | 100 | MG | QD | |||||||
| 127118991 | 12711899 | 11 | C | CALCIUM CARBONATE W/COLECALCIFEROL | CALCIUM CARBONATECHOLECALCIFEROL | 1 | Oral | 0 | |||||||||||
| 127118991 | 12711899 | 12 | C | VITARUBIN | CYANOCOBALAMIN | 1 | Subcutaneous | 1000 ?G, UNK | 0 | 1000 | UG | ||||||||
| 127118991 | 12711899 | 13 | C | FRAGMIN | DALTEPARIN SODIUM | 1 | Subcutaneous | WAS NOT COMBINED WITH XARELTO | 0 | ||||||||||
| 127118991 | 12711899 | 14 | C | Aspirin Cardio 300 | ASPIRIN | 1 | 100 MG, QD | 0 | 100 | MG | COATED TABLET | QD | |||||||
| 127118991 | 12711899 | 15 | C | XARELTO | RIVAROXABAN | 1 | Oral | NOT COMBINED WITH FRAGMIN | 0 | FILM-COATED TABLET | |||||||||
| 127118991 | 12711899 | 16 | C | ANDREAFOL | 2 | Oral | 0 | ||||||||||||
| 127118991 | 12711899 | 17 | C | PRIMPERAN | METOCLOPRAMIDE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 127118991 | 12711899 | 18 | C | DAFALGAN | ACETAMINOPHEN | 1 | Oral | 0 | |||||||||||
| 127118991 | 12711899 | 19 | C | ONDANSETRON | ONDANSETRON | 1 | 0 | ||||||||||||
| 127118991 | 12711899 | 20 | C | SOLU-MEDROL | METHYLPREDNISOLONE SODIUM SUCCINATE | 1 | Intravenous drip | 0 | |||||||||||
| 127118991 | 12711899 | 21 | C | Fortecortin | DEXAMETHASONE | 1 | Oral | 0 | |||||||||||
| 127118991 | 12711899 | 22 | C | EMEND | APREPITANT | 1 | Oral | 0 | |||||||||||
| 127118991 | 12711899 | 23 | C | OPTIDERM | 2 | Topical | 0 | ||||||||||||
| 127118991 | 12711899 | 24 | C | MOMETASONE FUROATE. | MOMETASONE FUROATE | 1 | Topical | 0 | |||||||||||
| 127118991 | 12711899 | 25 | C | EUTHYROX | LEVOTHYROXINE SODIUM | 1 | 0.5 X 50 MCG PER DAY | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127118991 | 12711899 | 1 | Computerised tomogram thorax |
| 127118991 | 12711899 | 2 | Lung adenocarcinoma stage IV |
| 127118991 | 12711899 | 3 | Lung adenocarcinoma |
| 127118991 | 12711899 | 4 | Lung adenocarcinoma stage IV |
| 127118991 | 12711899 | 5 | Hypertension |
| 127118991 | 12711899 | 6 | Hypertension |
| 127118991 | 12711899 | 7 | Product used for unknown indication |
| 127118991 | 12711899 | 8 | Computerised tomogram thorax |
| 127118991 | 12711899 | 13 | Administration site thrombosis |
| 127118991 | 12711899 | 15 | Administration site thrombosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127118991 | 12711899 | DS |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127118991 | 12711899 | Chronic kidney disease | |
| 127118991 | 12711899 | Drug interaction |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127118991 | 12711899 | 1 | 20160222 | 20160222 | 0 | |
| 127118991 | 12711899 | 2 | 20160126 | 20160331 | 0 | |
| 127118991 | 12711899 | 3 | 20160421 | 20160614 | 0 | |
| 127118991 | 12711899 | 4 | 20160126 | 20160331 | 0 | |
| 127118991 | 12711899 | 5 | 2016 | 2016 | 0 | |
| 127118991 | 12711899 | 6 | 2016 | 2016 | 0 | |
| 127118991 | 12711899 | 7 | 201601 | 0 | ||
| 127118991 | 12711899 | 8 | 20160415 | 20160719 | 0 | |
| 127118991 | 12711899 | 23 | 201602 | 201603 | 0 | |
| 127118991 | 12711899 | 24 | 201602 | 201603 | 0 |